Arkolith/Insider Trading/XLO/Form 4

Gilead Sciences, Inc.

10% OwnerXilio Therapeutics, Inc. (XLO) · full profile →Form 4 · filed Jun 6, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
0 non-derivative · 4 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 5, 2025Buy(P)13.3M——13.3M
Jun 5, 2025Buy(P)13.3M——23.3M
Jun 5, 2025Buy(P)13.3M——13.3M
Jun 5, 2025Buy(P)13.3M——13.3M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-25-011170) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML